x

Posted 21 June, 2021

ALTEROLA BIOTECH INC. appointed new CEO

CEO Change detected for ticker OTC:ABTI in a 8-K filed on 21 June, 2021.


  On June 21, 2021, the board of directors accepted the resignations of Timothy Rogers as Chief Executive Officer and Seamus McAuley as Chief Commercial Officer.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of ALTEROLA BIOTECH INC.
Health Care/Life Sciences • Pharmaceuticals
Alterola Biotech, Inc. is a pharmaceutical company, which engages in developing cannabinoid and cannabinoid-like molecules. It focuses on new medicines from all sources including botanical, traditional chemical synthesis, and biosynthetic methodologies. The company was founded on July 11, 2008 and is headquartered in Birkenhead, the United Kingdom.
Market Cap
$5.81M
View Company Details
ALTEROLA BIOTECH INC. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On June 21, 2021, the board of directors accepted the resignations of Timothy Rogers as Chief Executive Officer and Seamus McAuley as Chief Commercial Officer.


Also on June 21, 2021, we have appointed the following officers and directors: Tim Rogers as the Chairman of the Board, Colin Stott as Chief Operating Officer and Director, and Seamus McAuley as Chief Executive Officer.


Timothy Paul Rogers - Director /Chairman - Age 57


The employment history for Mr. Rogers is contained in Form 10-KT filed with the SEC on June 9, 2021.

 

Seamus McAuley - Chief Executive Officer- Age 45


The employment history for Mr. McAuley is contained in Form 10-KT filed with the SEC on June 9, 2021.


Colin Stott - Chief Operating Officer and Director - Age 54


From November 2020 - present, Mr. Stott has been Founder and Chief Executive Officer of Phytotherapeutix Holdings Ltd. From April 2019 - present, Mr. Stott has been Founder and Chief Executive Officer of Phytotherapeutix Ltd. From July 1, 2019 - December 1, 2020, he served as Chief Operating Officer for Alinova Biosciences Ltd. From June 1, 2017 - May 31, 2019, he served as Scientific Affairs Director, International Division for GW Pharmaceuticals plc. From January 2001 - May 31, 2017, he was R & D Operations Director for GW Pharmaceuticals plc.


Aside from the following, none of our new officers has had any material direct or indirect interest in any of our transactions or proposed transactions over the last two years. On January 19, 2021, we entered into a Stock Purchase Agreement with ABTI Pharma Limited, a company registered in England and Wales ("ABTI Pharma"), pursuant to which we acquired all of the outstanding shares of capital stock of ABTI Pharma from its shareholders in exchange for 600,000,000 shares of our company pro rata to the ABTI Pharma shareholders.


Also, we plan to enter into employment agreements with our executive officers once we raised sufficient capital to meet the financial obligations under those agreements.

There are no family relationships between any of the foregoing appointees and any of our directors or executive officers.


2